ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

First Page		Document Content
Date: 2014-02-27 10:08:11 Rituximab B-cell chronic lymphocytic leukemia Alemtuzumab CD20 Hepatitis B HBsAg Cytokine release syndrome Medicine Ofatumumab Pharmacology		ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Add to Reading List Source URL: www.ema.europa.eu Download Document from Source Website File Size: 349,15 KB Share Document on Facebook

	Gene Transfer Safety Assessment Board Adverse Event Report NIH Office of Biotechnology Activities December 2013 Protocol Number: Protocol Title: DocID: FsCj - View Document
	1 Session IV: Scientific and Commercial Challenges Review of Selected DocID: Ezze - View Document
	1 Session IV: Scientific and Commercial Challenges Review of Selected DocID: Cmz1 - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. • DocID: oahP - View Document
	Arzerra II-27 Final DHPC and communication plan DocID: nCSk - View Document